135 related articles for article (PubMed ID: 37029843)
21. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
23. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
24. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
[TBL] [Abstract][Full Text] [Related]
27. FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
Zhang S; Yan D; Sun Q; Du T; Cao D; Yang Y; Yuan B; Li H; Jiang X; Song C
Can J Gastroenterol Hepatol; 2020; 2020():1702823. PubMed ID: 32566545
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
29. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer.
Wang G; Zhao J; Song Y; Zhang W; Sun Y; Zhou A; Huang J; Du F; Yang L
BMC Cancer; 2018 May; 18(1):547. PubMed ID: 29743043
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Catenacci DVT; Chase L; Lomnicki S; Karrison T; de Wilton Marsh R; Rampurwala MM; Narula S; Alpert L; Setia N; Xiao SY; Hart J; Siddiqui UD; Peterson B; Moore K; Kipping-Johnson K; Markevicius U; Gordon B; Allen K; Racette C; Maron SB; Liao CY; Polite BN; Kindler HL; Turaga K; Prachand VN; Roggin KK; Ferguson MK; Posner MC
JAMA Netw Open; 2020 Feb; 3(2):e1921290. PubMed ID: 32058557
[TBL] [Abstract][Full Text] [Related]
32. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Zhao Q; Li Y; Huang J; Fan L; Tan B; Tian Y; Yang P; Jiao Z; Zhao X; Zhang Z; Wang D; Liu Y
Pharmazie; 2017 Apr; 72(4):236-240. PubMed ID: 29441995
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
[TBL] [Abstract][Full Text] [Related]
35. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
36. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
38. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
39. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
